Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12401055 | 0.83 | GPR119 (0.35) | GPR119 | |
| SCHEMBL3363728 | 0.79 | GPR119 (0.38) | GPR119 | |
| SCHEMBL26641764 | 0.76 | GPR119 (0.34) | GPR119 | |
| SCHEMBL1192952 | 0.75 | GPR119 (0.35) | GPR119 | |
| SCHEMBL2212358 | 0.75 | GPR119 (0.35) | GPR119 | |
| SCHEMBL102412 | 0.75 | GPR119 (0.38) | GPR119 | |
| SCHEMBL2566468 | 0.74 | SIGMAR1 (0.36) | GPR119 | |
| SCHEMBL22858014 | 0.74 | GPR119 (0.36) | GPR119 | |
| SCHEMBL732476 | 0.74 | GPR119 (0.41) | GPR119 | |
| SCHEMBL87245 | 0.74 | POLB (0.42) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10472328-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10207996-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472328-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | GPR119 52/4885 |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | GPR119 52/4885 |
| US-10207996-B2 | PKM2 modulators and methods for their use | PDK1, PDK2, PKM | GPR119 52/4885 |
| US-20200237766-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | PDK1, PDK2, PCK2 | GPR119 420/4885 |
| US-20190119219-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | GPR119 52/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | GPR119 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.